BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 8884827)

  • 21. A nationwide clinical survey of patients with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma in Japan.
    Iihara M; Yamashita T; Okamoto T; Kanbe M; Yamazaki K; Egawa S; Yamaguchi K; Obara T
    Jpn J Clin Oncol; 1997 Jun; 27(3):128-34. PubMed ID: 9255265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma.
    Hofstra RM; Landsvater RM; Ceccherini I; Stulp RP; Stelwagen T; Luo Y; Pasini B; Höppener JW; van Amstel HK; Romeo G
    Nature; 1994 Jan; 367(6461):375-6. PubMed ID: 7906866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation.
    Jasim S; Ying AK; Waguespack SG; Rich TA; Grubbs EG; Jimenez C; Hu MI; Cote G; Habra MA
    Thyroid; 2011 Feb; 21(2):189-92. PubMed ID: 21186952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Analysis of mutations in the RET proto-oncogene in patients with medullary thyroid tumor].
    Amosenko FA; Brzhezovskiĭ VZh; Liubchenko LN; Shabanov MA; Kozlova VM; Vanushko VE; Kazubskaia TP; Gar'kavtseva RF; Kalinin VN
    Genetika; 2003 Jun; 39(6):847-54. PubMed ID: 12884527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma.
    Iwashita T; Kato M; Murakami H; Asai N; Ishiguro Y; Ito S; Iwata Y; Kawai K; Asai M; Kurokawa K; Kajita H; Takahashi M
    Oncogene; 1999 Jul; 18(26):3919-22. PubMed ID: 10445857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.
    Eng C; Smith DP; Mulligan LM; Nagai MA; Healey CS; Ponder MA; Gardner E; Scheumann GF; Jackson CE; Tunnacliffe A
    Hum Mol Genet; 1994 Feb; 3(2):237-41. PubMed ID: 7911697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular mechanisms of development of multiple endocrine neoplasia 2 by RET mutations.
    Takahashi M; Asai N; Iwashita T; Murakami H; Ito S
    J Intern Med; 1998 Jun; 243(6):509-13. PubMed ID: 9681851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prophylactic total thyroidectomy in children and adolescents with genetic mutations in the RET-protooncogene].
    Spinelli C; Puccini M; Bertocchini A; Lima M; Pacini F; Miccoli P
    Pediatr Med Chir; 2002; 24(1):53-7. PubMed ID: 11938683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
    Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU
    Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A single missense mutation in codon 918 of the RET proto-oncogene in sporadic medullary thyroid carcinomas.
    Maeda S; Namba H; Takamura N; Tanigawa K; Takahashi M; Noguchi S; Nagataki S; Kanematsu T; Yamashita S
    Endocr J; 1995 Apr; 42(2):245-50. PubMed ID: 7627269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.
    Eng C; Mulligan LM; Smith DP; Healey CS; Frilling A; Raue F; Neumann HP; Ponder MA; Ponder BA
    Clin Endocrinol (Oxf); 1995 Jul; 43(1):123-7. PubMed ID: 7641404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic testing for familial cancer. Consequences of RET proto-oncogene mutation analysis in multiple endocrine neoplasia, type 2.
    Learoyd DL; Marsh DJ; Richardson AL; Twigg SM; Delbridge L; Robinson BG
    Arch Surg; 1997 Sep; 132(9):1022-5. PubMed ID: 9301617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation.
    Miyauchi A; Futami H; Hai N; Yokozawa T; Kuma K; Aoki N; Kosugi S; Sugano K; Yamaguchi K
    Jpn J Cancer Res; 1999 Jan; 90(1):1-5. PubMed ID: 10076558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A two-hit model for development of multiple endocrine neoplasia type 2B by RET mutations.
    Iwashita T; Murakami H; Kurokawa K; Kawai K; Miyauchi A; Futami H; Qiao S; Ichihara M; Takahashi M
    Biochem Biophys Res Commun; 2000 Feb; 268(3):804-8. PubMed ID: 10679286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Germ line mutations of the ret proto-oncogene in Japanese patients with multiple endocrine neoplasia type 2A and type 2B.
    Maruyama S; Iwashita T; Imai T; Funahashi H; Ceccherini I; Luo Y; Romeo G; Matsuo S; Matsuyama M; Takahashi M
    Jpn J Cancer Res; 1994 Sep; 85(9):879-82. PubMed ID: 7961113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B.
    Carlson KM; Dou S; Chi D; Scavarda N; Toshima K; Jackson CE; Wells SA; Goodfellow PJ; Donis-Keller H
    Proc Natl Acad Sci U S A; 1994 Feb; 91(4):1579-83. PubMed ID: 7906417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parent-of-origin effects in multiple endocrine neoplasia type 2B.
    Carlson KM; Bracamontes J; Jackson CE; Clark R; Lacroix A; Wells SA; Goodfellow PJ
    Am J Hum Genet; 1994 Dec; 55(6):1076-82. PubMed ID: 7977365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oncogenic activation of the ret protooncogene in thyroid cancer.
    Takahashi M
    Crit Rev Oncog; 1995; 6(1):35-46. PubMed ID: 8573606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Detection of RET-proto-oncogene mutations in the diagnosis of Type 2 endocrine neoplasia (MEN 2)].
    Komminoth P; Muletta-Feurer S; Soltermann A; Gemsenjäger E; Bürgi H; Staub JJ; Schönle E; Fried M; Vetter W; Spinas GA; Heitz PU
    Schweiz Med Wochenschr; 1996 Aug; 126(31-32):1329-38. PubMed ID: 8765374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group.
    Frank-Raue K; Höppner W; Frilling A; Kotzerke J; Dralle H; Haase R; Mann K; Seif F; Kirchner R; Rendl J; Deckart HF; Ritter MM; Hampel R; Klempa J; Scholz GH; Raue F
    J Clin Endocrinol Metab; 1996 May; 81(5):1780-3. PubMed ID: 8626834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.